<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">
Go Back

Biodesix Secures $10 Million in Series B-1 Funding

Funding to further the commercialization of VeriStrat®

Biodesix, Inc., a privately held molecular diagnostics company focused on proteomic-based diagnostics discovery and commercialization, announced today that it has completed the initial tranche of its $10 million Series B-1 financing round. The financing was led by existing shareholders and members of the Board of Directors.

“We are excited with the progress the company has made since launching our first product, VeriStrat,” said David Brunel, CEO. “With the help of our existing investors, we will further the commercialization and development of VeriStrat as well as continue developing our unique portfolio of diagnostic products focused on personalized medicine.”

About Veristrat

VeriStrat is a pretreatment serum, proteomic test for patients with advanced NSCLC. The test identifies patients who are likely to have good or poor outcomes after treatment with EGFR-TKIs. Samples are processed in Biodesix’ CLIA accredited laboratory and results are typically reported within 72 hours of sample shipment. VeriStrat has been validated in clinical studies with over 1000 patients. Biodesix is engaging in additional studies to further validate the test and to explore the clinical utility of VeriStrat in other solid epithelial tumors and with other EGFR inhibitors. For more information on VeriStrat or to order VeriStrat, visit www.VeriStratSupport.com or call the VeriStrat Support Hotline at 1-866-432-5930.

About Biodesix

Biodesix is a fully integrated molecular diagnostic company enabling personalized health care using mass spectrometry-based molecular profiling. Working with academic and biopharma collaborators, Biodesix uses its proprietary technology, ProTS® to discover and validate diagnostic tests that improve patient outcomes. Biodesix’ first product, VeriStrat, is commercially available for physicians to help guide their treatment of patients with non-small cell lung cancer. For more information on Biodesix, visit www.Biodesix.com.

This press release contains statements that are hereby identified as “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company’s inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company’s financial resources will be insufficient to meet the Company’s business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.

Topics: B-1 funding, biomarker, blood-based cancer test, cancer diagnostics, EGFR, Press Releases, liquid biopsy, lung cancer, molecular diagnostic, Non-Small Cell Lung Cancer, NSCLC, oncology